Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Paris Brain Institute, |
RCV001391527 | SCV001451060 | pathogenic | Hereditary spastic paraplegia 7 | criteria provided, single submitter | clinical testing | ||
Genetic Services Laboratory, |
RCV001819969 | SCV002064533 | likely pathogenic | not provided | 2021-06-18 | criteria provided, single submitter | clinical testing | DNA sequence analysis of the SPG7 gene demonstrated a sequence change,c.1730G>A, in exon 13 that results in an amino acid change, p.Gly577Asp. This sequence change is absent in the gnomAD population database. The p.Gly577Asp change has been previously described in the compound heterozygous state in one individual with spastic paraplegia (PMID: 21623769). Another different sequence change affecting the same amino acid (p.Gly577Ser) has also been reported in the compound heterozygous state in one individual with spastic paraplegia (PMID: 14985266). The p.Gly577Asp change affects a highly conserved amino acid residue located in the zinc binding motif of the SPG7 protein. The p.Gly577Asp substitution appears to be deleterious using several in-silico pathogenicity prediction tools (SIFT, PolyPhen2, Align GVGD, REVEL). Overall, this evidence suggests p.Gly577Asp is likely pathogenic, however functional studies have not been performed to prove this conclusively. |
Revvity Omics, |
RCV001391527 | SCV003820053 | uncertain significance | Hereditary spastic paraplegia 7 | 2021-01-14 | criteria provided, single submitter | clinical testing |